Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Soliris Eculizumab Hemolytic Uremic Syndrome, Atypical Do not list Complete
Soliris eculizumab Myasthenia Gravis (gMG), adults Reimburse with clinical criteria and/or conditions Complete
Somatuline Autogel Lanreotide acetate Acromegaly List in a similar manner to other drugs in class Complete
Somavert Pegvisomant acromegaly Do not list Complete
Sotyktu deucravacitinib Psoriasis, moderate to severe plaque Do not reimburse Complete
Sovaldi Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete
Sovaldi sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Spevigo spesolimab generalized pustular psoriasis (GPP) Active
Spinraza Nusinersen Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions Complete
Spinraza nusinersen Spinal Muscular Atrophy Do not reimburse Complete